Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

SiYaWe May. 9 at 2:42 PM

$CVM Did anyone else know or see Geert’s presentation at this last week? https://www.marketmoverssummit.com

0 · Reply

SmallCapGrowth May. 8 at 5:20 PM

$CVM #nasdaq CEL-SCI Corporation - Investors Hangout MVP's https://investorshangout.com/post/view?id=6828571

1 · Reply

SmallCapGrowth May. 8 at 4:08 PM

$CVM on watch: CEL‑SCI’s Multikine could produce a major 2026 catalyst — high risk, high reward. Read the full alert: https://wix.to/kDnRDcg #CVM #CELSCI #StockAlert #Biotech #ClinicalTrials

0 · Reply

SmallCapGrowth May. 8 at 4:02 PM

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies. https://www.youtube.com/watch?v=MZQt_BY761M

0 · Reply

SmallCapGrowth May. 8 at 3:14 PM

Daily Hot Plays : $CVM #nasdaq CEL-SCI Corporation is a bi... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177583585 via @Investors_Hub

0 · Reply

DrDizrespect May. 8 at 3:09 PM

$CVM 😂😂😂😂 basically what you buy with a purchase of CVM. 👌🏽

0 · Reply

forthewinwin May. 8 at 1:57 PM

$CVM So much riding on SFDA's decision. Would be great to see a much-needed treatment to help people and save lives. Even if the stock tanks (I don't think it will), traders will have invested in research to better humanity. I long to see a win-win here for patients and investors!

4 · Reply

SmallCapGrowth May. 8 at 1:16 PM

$CVM on watch: CEL‑SCI’s Multikine could produce a major 2026 catalyst — high risk, high reward. Read the full alert: https://wix.to/kDnRDcg #CVM #CELSCI #StockAlert #Biotech #ClinicalTrials @thebullrunshow

0 · Reply

Isitreallyhim May. 8 at 12:50 PM

$CVM Ding Ding Ding Round two complete. The easy winner was the permabaggers. With the amount of dilution and the stock rising a bit and @BioGLovesMe and @ImmxBeliever just throwing around old news and old pictures and saying nothing important, it was an easy win for the perma bunch. If the price holds with more dilution today, I think we all know that the SFDA decision is getting closer.....Cheers

1 · Reply

SmallCapGrowth May. 8 at 12:41 PM

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies. https://www.youtube.com/watch?v=MZQt_BY761M @thebullrunshow

0 · Reply

CEL-SCI files to sell 3.44M shares of common stock

Feb 18, 2026, 9:00 AM EST - 2 months ago

CEL-SCI Reports Fiscal First Quarter 2026 Results

Dec 29, 2025, 9:00 AM EST - 4 months ago

CEL-SCI Reports Fiscal 2025 Results

2025-11-07T21:35:28.000Z - 6 months ago

CEL-SCI files to sell 375,000 shares of common stock for holders

Oct 20, 2025, 9:00 AM EDT - 7 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 10, 2025, 8:00 AM EDT - 7 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Aug 29, 2025, 12:52 PM EDT - 9 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

2025-08-28T03:45:10.000Z - 9 months ago

CEL-SCI 1.11M share Spot Secondary priced at $9.00

Aug 27, 2025, 10:35 PM EDT - 9 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

2025-08-27T21:30:16.000Z - 9 months ago

CEL-SCI announces common stock offering, no amount given

Aug 27, 2025, 5:25 PM EDT - 9 months ago

CEL-SCI Announces Proposed Public Offering

2025-08-14T14:50:29.000Z - 9 months ago

CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year

Aug 14, 2025, 10:45 AM EDT - 9 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

2025-08-13T13:25:31.000Z - 9 months ago

CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia

Aug 13, 2025, 9:15 AM EDT - 9 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 10 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

2025-07-11T16:25:25.000Z - 10 months ago

CEL-SCI announces pricing of $5.7M at-the-market common stock offering

Jul 11, 2025, 12:16 PM EDT - 10 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

2025-07-11T13:25:08.000Z - 10 months ago

CEL-SCI teams with Saudi Arabia pharmaceutical, healthcare company for Multikine

Jul 11, 2025, 9:15 AM EDT - 10 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 11 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 23, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of Public Offering

2025-05-22T00:40:14.000Z - 1 year ago

CEL-SCI 2M share Spot Secondary priced at $2.50

May 21, 2025, 8:14 PM EDT - 1 year ago

CEL-SCI Announces Pricing of Public Offering

2025-05-21T20:10:52.000Z - 1 year ago

CEL-SCI announces common stock offering, no amount given

2025-05-21T12:05:38.000Z - 1 year ago

CEL-SCI completes Breakthrough Medicine Designation application for Multikine

May 21, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

2025-05-19T18:45:05.000Z - 1 year ago

CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20

May 19, 2025, 2:40 PM EDT - 1 year ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 1 year ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

2025-04-08T13:55:25.000Z - 1 year ago

CEL-SCI says publication supports strategy to seek early approval for multikine

Apr 8, 2025, 9:51 AM EDT - 1 year ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

2025-03-25T19:48:17.000Z - 1 year ago

CEL-SCI publishes new data from Multikine study

Mar 24, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jun 18, 2024, 8:00 AM EDT - 2 years ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

May 16, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Apr 23, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 2 years ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Mar 19, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

SiYaWe May. 9 at 2:42 PM

$CVM Did anyone else know or see Geert’s presentation at this last week? https://www.marketmoverssummit.com

0 · Reply

SmallCapGrowth May. 8 at 5:20 PM

$CVM #nasdaq CEL-SCI Corporation - Investors Hangout MVP's https://investorshangout.com/post/view?id=6828571

1 · Reply

SmallCapGrowth May. 8 at 4:08 PM

$CVM on watch: CEL‑SCI’s Multikine could produce a major 2026 catalyst — high risk, high reward. Read the full alert: https://wix.to/kDnRDcg #CVM #CELSCI #StockAlert #Biotech #ClinicalTrials

0 · Reply

SmallCapGrowth May. 8 at 4:02 PM

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies. https://www.youtube.com/watch?v=MZQt_BY761M

0 · Reply

SmallCapGrowth May. 8 at 3:14 PM

Daily Hot Plays : $CVM #nasdaq CEL-SCI Corporation is a bi... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177583585 via @Investors_Hub

0 · Reply

DrDizrespect May. 8 at 3:09 PM

$CVM 😂😂😂😂 basically what you buy with a purchase of CVM. 👌🏽

0 · Reply

forthewinwin May. 8 at 1:57 PM

4 · Reply

SmallCapGrowth May. 8 at 1:16 PM

0 · Reply

Isitreallyhim May. 8 at 12:50 PM

1 · Reply

SmallCapGrowth May. 8 at 12:41 PM

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies. https://www.youtube.com/watch?v=MZQt_BY761M @thebullrunshow

0 · Reply

BioGLovesMe May. 7 at 5:38 PM

$CVM Of course the geriatric comes back on a dead cat bounce. No mention that his bag is now close to -$40K. The P3 failed, Geert datamined a new target population, and no meaningful developments have occurred in the close to 5 years since the P3 fail was revealed. The FDA didn't approve this, the Canadians/British/EU didn't want it, and the Saudis don't want it. They have no money, a 30 working day decision still hasn't been made in now 180 wotking days, and the confirmatory trial still hasn't started. Longs, you have lost. Admit it, realize your loss, and move on.

1 · Reply

DeepThought May. 7 at 3:54 PM

$CVM @SemiRetiredEngineer You should really change your name to SemiRetiredClown!

0 · Reply

drkazmd65 May. 7 at 3:06 PM

$CVM - I mean, I know we are down a bunch the last week or two, but up 18+% on the day with a lot more volume than is typical. Can't find any news driving it yet.

2 · Reply

Cruiser24 May. 7 at 2:44 PM

$CVM BULLISH Could this be a 3m volume day? Who knows? I do know one thing though. One day closer. GOOD. LUCK. BULLS. 💎💎💎💎✋🤚💎💎💎💎

2 · Reply

Thebullrun May. 7 at 1:49 PM

$CVM let’s rock n rolll!

1 · Reply

Cruiser24 May. 7 at 1:17 PM

$CVM BULLISH Who really knows what is going to be the ending of this soap opera? I’m still a believer in Multikine. I saw the results of phase 3. I still believe if the patients with the low LD1 had not been given the chemo the results would have been far better. That is why I bought and that is why I will stay until the day it is announced good or bad. One thing I know I figured right on and that is this. One day closer. GOOD LUCK BULLS 💎💎💎💎✋🤚💎💎💎💎

1 · Reply

Isitreallyhim May. 7 at 12:28 PM

$CVM Ding Ding Ding Round 1 is complete and the judges score a win for the Geert haters. With this kind of stock drop and some valid points they definitely threw some good uppercuts and one left hook that landed. Good luck to both teams in Round 2

1 · Reply

BioGLovesMe May. 7 at 5:19 AM

$CVM The degenerate Kraut gambler is working on a few copium-addled falsehoods: -The bar for approving a new clinical trial is that patient safety is maintained, and the design is approprite to answer the questions of the trial. Neither of those mean the FDA "validated" anything. -The new "target population" WAS datamined post-hoc, and yes, this was to salvage it to get the FDA to approve a clinical trial redo. If the current dataset was good enough this wouldn't be required and a BLA would have been submitted. -Continuous dilution is not "standard", and no approved products/revenue isn't "trivial" when your company is 43 years old. -There has been 5 years of delay now since the TLR readout in 2021. Also, the trial is estimated to take at least 2 years to even get early data. So much for speedy. This is why share price is, once again, near all time lows.

1 · Reply

Mey636363 May. 7 at 3:21 AM

$CVM 💩🕳️🤮💩🕳️🤮💩🕳️🤮

0 · Reply

BooBoo1868 May. 6 at 8:43 PM

$CVM another great day....

0 · Reply

Thebullrun May. 6 at 8:24 PM

$CVM

1 · Reply

Market Cap	13.59M
Revenue (ttm)	0.00
Net Income (ttm)	-25.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	353,900
Avg Vol	143,440
Day's Range	N/A - N/A
Shares Out	8.49M
Stochastic %K	14%
Beta	0.70
Analysts	Strong Sell
Price Target	$180.18